Application value of circulating tumor cells in the diagnosis and treatment of lung tumor patients
Objective To analyze the clinical application value of circulating tumor cells(CTCs)in the diagnosis and treatment of lung tumor patients.Methods A total of 14 patients with benign lung tumors and 40 patients with malignant lung tumors admitted to the thoracic surgery department of our hospi-tal from April 2020 to April 2022 were selected.The CTCs levels of patients before and one month after surgery were detected using ligand targeted polymerase chain reaction(PCR).The relationship between pe-ripheral blood CTCs levels and clinical data was analyzed,and the patients were followed up.Data were analyzed using chi-square test,Wilcoxon rank sum test,and Cox regression.Results The positive rate of CTCs in patients with malignant lung tumors was significantly higher than that in patients with benign lung tumors[75.0％(30/40)vs.35.7％(5/14),x2=7.018,P＜0.05].The positive expression rate of CTCs was not significantly correlated with gender,age and histological type(x2=0.320,2.133,0.076,P＞0.05),but with tumor pathological stage(x2=3.372,P＜0.001)and maximum diameter(x2=3.843,P＜0.001).Positive CTC was a risk factor for postoperative metastasis and recurrence in lung cancer patients[hazard ratio(HR):0.145,95％confidence interval(CI):0.031-0.685,P＜0.05].Conclusion The level of CTCs in lung cancer patients is correlated with tumor TNM staging,which is beneficial for determining the nature of lung nodules,aiding in the diagnosis of lung tumors,prognosis e-valuation,and postoperative guidance for treatment.
NETL
NSTL
万方数据
